We are live on ! Find out more
STSA

Satsuma Pharmaceuticals, Inc. Common Stock
STSA

Delisted

STSA was delisted on the 7th of June, 2023.

Back to rankings

30 hedge funds and large institutions have $202M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
+30
Holders Change %
–
% of All Funds
0.66%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
30
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$72.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$37.3M
3
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
+$29.3M
4
Citadel Advisors
Citadel Advisors
Florida
+$14.9M
5
CC
Caxton Corporation
New Jersey
+$13.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
26
Tyers Asset Management
Texas
$16K +$16.6K +1,072 New
UBS Group
27
UBS Group
Switzerland
$8K +$8.58K +553 New
CCA
28
Catalyst Capital Advisors
New York
$5K +$5.17K +333 New
FIA
29
FNY Investment Advisers
New York
$4K +$4.65K +300 New
Morgan Stanley
30
Morgan Stanley
New York
$2K +$1.55K +100 New
1
2

STSA Hedge Fund Activity: Q3 2019 in Review

30 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q3 2019, worth a combined $202M.

Buyers outnumbered sellers: 30 funds opened new STSA positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $72.6M.

  • 30 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q3 2019, up from 0 in Q2 2019.
  • Funds reported $202M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q3 2019.
  • 30 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 0 closed out, a net change of +30 holders.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was RA Capital Management, an estimated $72.6M added.

Based on aggregated 13F filings for Q3 2019.